Supernus Pharmaceuticals Q2 2024 GAAP EPS $0.36 Beats $0.05 Estimate, Sales $168.300M Beat $148.851M Estimate
Supernus Pharmaceuticals Q2 2024 GAAP EPS $0.36 Beats $0.05 Estimate, Sales $168.300M Beat $148.851M Estimate
supernus pharmaceuticals 2024年第二季度的GAAP每股收益为0.36美元，超过0.05美元的估计值，销售额为1.683亿美元，超过1.48851亿美元的估计值。
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.05 by 620 percent. The company reported quarterly sales of $168.300 million which beat the analyst consensus estimate of $148.851 million by 13.07 percent. This is a 24.15 percent increase over sales of $135.563 million the same period last year.
Supernus Pharmaceuticals（纳斯达克股票代码SUPN）报告每股盈利0.36美元，超出分析师平均预期的0.05美元，增幅达620%。该公司季度销售额为1.683亿美元，超出分析师平均预期的1.48851亿美元，增幅为13.07%。这是去年同期1.35563亿美元销售额的增长24.15%。